[Development of research for drug-resistance mechanism of taxol].
[Development of research for drug-resistance mechanism of taxol].
The resistant problem is the main restriction factor for clinical usage of taxol. The main mechanism of its resistance includes the high expression of P-gp, beta- and alpha-tubulin isotypes, the alteration expression of PKC, Bcl-2, p53, and ErbB2. The reversing method includes the use of analogues of taxol to reduce the expression of P-gp, or the use of antibody, immunotoxin, antisence oligonucleotide, and liposomes. The combination with other drugs can also be a method to reverse the resistance of taxol.
Paclitaxel, Immunotoxins, Apoptosis, Antineoplastic Agents, Phytogenic, Oligodeoxyribonucleotides, Antisense, Drug Resistance, Neoplasm, Tubulin, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1
Paclitaxel, Immunotoxins, Apoptosis, Antineoplastic Agents, Phytogenic, Oligodeoxyribonucleotides, Antisense, Drug Resistance, Neoplasm, Tubulin, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!